Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary

Alzamend Neuro

27/07/2026 22:01

Alzamend Neuro Inc ALZN.OQ reported a quarterly adjusted loss of 47 cents​​ per share for the quarter ended April 30.  The lone analyst forecast for the quarter was for a loss of 67 cents per share. 
Reported revenue was zero​; analysts expected zero. 
Alzamend Neuro Inc's reported EPS for the quarter was a loss of 47 cents​.
The company reported a quarterly loss of $2.87 million.
Alzamend Neuro Inc shares had risen by 10.8% this quarter and lost 26.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 7.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Alzamend Neuro Inc is $25.00, about 94.7% above its last closing price of $1.33
This summary was machine generated from LSEG data July 27 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Apr. 30 2026 
-0.67
-0.47
Beat
Jan. 31 2026 
-1.92
-0.58
Beat
Oct. 31 2025 
-1.95
-0.30
Beat
Jul. 31 2025 
-0.69
-1.28
Missed